89bio Market Capitalization from 2010 to 2024
| ETNB Stock | USD 8.38 0.40 5.01% |
Check 89bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among 89bio's main balance sheet or income statement drivers, such as Tax Provision of 10 K, Depreciation And Amortization of 82.9 K or Interest Expense of 4.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.74. 89bio financial statements analysis is a perfect complement when working with 89bio Valuation or Volatility modules.
89bio | Market Capitalization |
Latest 89bio's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of 89bio Inc over the last few years. It is 89bio's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in 89bio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 985.34 M | 10 Years Trend |
|
Market Cap |
| Timeline |
89bio Market Capitalization Regression Statistics
| Arithmetic Mean | 191,333,761 | |
| Geometric Mean | 155,894,182 | |
| Coefficient Of Variation | 69.07 | |
| Mean Deviation | 115,191,561 | |
| Median | 95,340,794 | |
| Standard Deviation | 132,150,824 | |
| Sample Variance | 17463.8T | |
| Range | 347.7M | |
| R-Value | 0.78 | |
| Mean Square Error | 7307.9T | |
| R-Squared | 0.61 | |
| Significance | 0.0006 | |
| Slope | 23,106,233 | |
| Total Sum of Squares | 244493.8T |
89bio Market Capitalization History
About 89bio Financial Statements
89bio stakeholders use historical fundamental indicators, such as 89bio's Market Capitalization, to determine how well the company is positioned to perform in the future. Although 89bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in 89bio's assets and liabilities are reflected in the revenues and expenses on 89bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in 89bio Inc. Please read more on our technical analysis and fundamental analysis pages.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California. 89Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether 89bio Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of 89bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of 89bio Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on 89bio Inc Stock:Check out the analysis of 89bio Correlation against competitors. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 89bio. If investors know 89bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 89bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Return On Assets (0.41) | Return On Equity (0.73) |
The market value of 89bio Inc is measured differently than its book value, which is the value of 89bio that is recorded on the company's balance sheet. Investors also form their own opinion of 89bio's value that differs from its market value or its book value, called intrinsic value, which is 89bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 89bio's market value can be influenced by many factors that don't directly affect 89bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 89bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if 89bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 89bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.